Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,568 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Publisher Correction: A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.
Seung E, Xing Z, Wu L, Rao E, Cortez-Retamozo V, Ospina B, Chen L, Beil C, Song Z, Zhang B, Levit M, Deng G, Hebert A, Kirby P, Li A, Poulton EJ, Vicente R, Garrigou A, Piepenhagen P, Ulinski G, Sanicola-Nadel M, Bangari DS, Qiu H, Pao L, Wiederschain D, Wei R, Yang ZY, Nabel GJ. Seung E, et al. Among authors: qiu h. Nature. 2022 Apr;604(7905):E13. doi: 10.1038/s41586-022-04652-x. Nature. 2022. PMID: 35332336 No abstract available.
A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.
Seung E, Xing Z, Wu L, Rao E, Cortez-Retamozo V, Ospina B, Chen L, Beil C, Song Z, Zhang B, Levit M, Deng G, Hebert A, Kirby P, Li A, Poulton EJ, Vicente R, Garrigou A, Piepenhagen P, Ulinski G, Sanicola-Nadel M, Bangari DS, Qiu H, Pao L, Wiederschain D, Wei R, Yang ZY, Nabel GJ. Seung E, et al. Among authors: qiu h. Nature. 2022 Mar;603(7900):328-334. doi: 10.1038/s41586-022-04439-0. Epub 2022 Feb 23. Nature. 2022. PMID: 35197632
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation.
Wu L, Seung E, Xu L, Rao E, Lord DM, Wei RR, Cortez-Retamozo V, Ospina B, Posternak V, Ulinski G, Piepenhagen P, Francesconi E, El-Murr N, Beil C, Kirby P, Li A, Fretland J, Vicente R, Deng G, Dabdoubi T, Cameron B, Bertrand T, Ferrari P, Pouzieux S, Lemoine C, Prades C, Park A, Qiu H, Song Z, Zhang B, Sun F, Chiron M, Rao S, Radošević K, Yang ZY, Nabel GJ. Wu L, et al. Among authors: qiu h. Nat Cancer. 2020 Jan;1(1):86-98. doi: 10.1038/s43018-019-0004-z. Epub 2019 Nov 18. Nat Cancer. 2020. PMID: 35121834
biAb Mediated Restoration of the Linkage between Dystroglycan and Laminin-211 as a Therapeutic Approach for α-Dystroglycanopathies.
Gumlaw N, Sevigny LM, Zhao H, Luo Z, Bangari DS, Masterjohn E, Chen Y, McDonald B, Magnay M, Travaline T, Yoshida-Moriguchi T, Fan W, Reczek D, Stefano JE, Qiu H, Beil C, Lange C, Rao E, Lukason M, Barry E, Brondyk WH, Zhu Y, Cheng SH. Gumlaw N, et al. Among authors: qiu h. Mol Ther. 2020 Feb 5;28(2):664-676. doi: 10.1016/j.ymthe.2019.11.023. Epub 2019 Dec 6. Mol Ther. 2020. PMID: 31843448 Free PMC article.
Engineered Fc-glycosylation switch to eliminate antibody effector function.
Zhou Q, Jaworski J, Zhou Y, Valente D, Cotton J, Honey D, Boudanova E, Beninga J, Rao E, Wei R, Mauriac C, Pan C, Park A, Qiu H. Zhou Q, et al. Among authors: qiu h. MAbs. 2020 Jan-Dec;12(1):1814583. doi: 10.1080/19420862.2020.1814583. MAbs. 2020. PMID: 32892677 Free PMC article.
Engineering an anti-CD52 antibody for enhanced deamidation stability.
Qiu H, Wei R, Jaworski J, Boudanova E, Hughes H, VanPatten S, Lund A, Day J, Zhou Y, McSherry T, Pan CQ, Sendak R. Qiu H, et al. MAbs. 2019 Oct;11(7):1266-1275. doi: 10.1080/19420862.2019.1631117. Epub 2019 Jul 18. MAbs. 2019. PMID: 31199181 Free PMC article.
6,568 results